GAMMA RADIATION STERILIZED NANOPARTICULATE DOCETAXEL COMPOSITIONS AND METHODS OF MAKING SAME

• US 20080220074A1
• Filed: 03/20/2008
• Published: 09/11/2008
• Est. Priority Date: 10/04/2002
• Status: Abandoned Application

• Current Assignee: Elan Pharma International Limited (Perrigo Company PLC)
• Original Assignee: Elan Corporation PLC (Perrigo Company PLC)
• Inventors: Bosch, H. William, Ryde, Niels, Keller, Janine
• Application Number:
  US12/052,436
• Publication Number:
  US 20080220074A1
• Time in Patent Office: Days
• US Class Current: 424/489
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 9/145 with organic compounds
• CPC Class Codes: A61K 9/146 with organic macromolecular compounds
• CPC Class Codes: A61L 2/0035 Gamma radiation
• CPC Class Codes: A61L 2/081 Gamma radiation
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Nanoparticulate compositions comprising docetaxel or a salt, derivative, conjugate or analogue thereof, wherein the compositions are terminally sterilized via gamma radiation, are described, as well as methods of making and using such compositions.

Claims

1. A sterile composition comprising:

(a) particles comprising at least one active agent selected from the group consisting of docetaxel, salts of docetaxel, derivatives of docetaxel, conjugates of docetaxel and analogues of docetaxel, wherein the particles have an effective average particle size of less than about 2000 nm; and

(b) at least one surface stabilizer adsorbed on a surface of the particles, wherein the composition is sterilized by exposure to gamma radiation.

2. The composition of claim 1, wherein the active agent is in a form selected from the group consisting of crystalline, amorphous, semi-crystalline, semi-amorphous, and mixtures thereof.

3. The composition of claim 1, wherein the active agent is docetaxel.

4. The composition of claim 3, wherein the docetaxel is in a form selected from the group consisting of an anhydrous, a hydrated, and a triydrate crystal form, and mixtures thereof.

5. The composition of claim 1, wherein the effective average particle size is selected from the group consisting of less than:

about 1900 nm, about 1800 nm, about 1700 nm, about 1600 nm, about 1500 nm, about 1400 nm, about 1300 nm, about 1200 nm, about 1100 nm, about 1000 nm, about 900 nm, about 800 nm, about 700 nm, about 650 nm, about 600 nm, about 550 nm, about 500 nm, about 450 nm, about 400 nm, about 350 nm, about 300 nm, about 250 nm, about 200 nm, about 150 nm, about 100 nm, about 75 nm, and about 50 nm.

6. The composition of claim 1, wherein the composition is formulated:

(a) for routes of administration selected from the group consisting of oral, pulmonary, rectal, opthalmic, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, local, buccal, nasal, and topical administration;

(b) into a dosage form selected from the group consisting of liquid dispersions, solid dispersions, liquid-filled capsules, gels, aerosols, ointments, creams, lyophilized formulations, tablets, capsules, multi-particulate filled capsules, tablets composed of multi-particulates, compressed tablets, and capsules filled with enteric-coated beads of the active agent;

(c) into a dosage form selected from the group consisting of controlled release formulations, fast melt formulations, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations;

or

(d) any combination of (a), (b), and (c).

7. The composition of claim 6, wherein the composition is an injectable formulation.

8. The composition of claim 6, wherein the composition is formulated for pulmonary administration.

9. The composition of claim 6, wherein the composition is in a solid form.

10. The composition of claim 6, wherein the composition is in a liquid form.

11. The composition of claim 1, wherein:

(a) the at least one surface stabilizer is present in an amount selected from the group consisting of about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99%, by weight, based on the total combined dry weight of the active agent and the at least one surface stabilizer, not including other excipients;

(b) the particles are present in an amount selected from the group consisting of about 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99%, by weight, based on the total combined weight of the particles comprising the active agent and the at least one surface stabilizer, not including other excipients;

or

(c) a combination of (a) and (b).

12. The composition of claim 1, wherein the at least one surface stabilizer is selected from the group consisting of an anionic surface stabilizer, a cationic surface stabilizer, a zwitterionic surface stabilizer, a non-ionic surface stabilizer, and an ionic surface stabilizer.

13. The composition of claim 1, wherein the at least one surface stabilizer is selected from the group consisting of povidone, cetyl pyridinium chloride, albumin, human serum albumin, bovine serum albumin, gelatin, casein, phosphatides, dextran, glycerol, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyethylene glycols, dodecyl trimethyl ammonium bromide, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, hydroxypropyl celluloses, hypromellose, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hypromellose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, polyvinylpyrrolidone, 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde, poloxamers;

poloxamines, a charged phospholipid, dioctylsulfosuccinate, dialkylesters of sodium sulfosuccinic acid, sodium lauryl sulfate, sodium deoxycholate, alkyl aryl polyether sulfonates, mixtures of sucrose stearate and sucrose distearate, p-isononylphenoxypoly-(glycidol), decanoyl-N-methylglucamide;

n-decyl b-D-glucopyranoside;

n-decyl b-D-maltopyranoside;

n-dodecyl b-D-glucopyranoside;

n-dodecyl b-D-maltoside;

heptanoyl-N-methylglucamide;

n-heptyl-b-D-glucopyranoside;

n-heptyl b-D-thioglucoside;

n-hexyl b-D-glucopyranoside;

nonanoyl-N-methylglucamide;

n-noyl b-D-glucopyranoside;

octanoyl-N-methylglucamide;

n-octyl-b-D-glucopyranoside;

octyl b-D-thioglucopyranoside;

lysozyme, PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, PEG-vitamin E, random copolymers of vinyl acetate and vinyl pyrrolidone, a cationic polymer, a cationic biopolymer, a cationic polysaccharide, a cationic cellulosic, a cationic alginate, a cationic nonpolymeric compound, a cationic phospholipids, cationic lipids, polymethylmethacrylate trimethylammonium bromide, sulfonium compounds, polyvinylpyrrolidone-2-dimethylaminoethyl methacrylate dimethyl sulfate, hexadecyltrimethyl ammonium bromide, phosphonium compounds, quarternary ammonium compounds, benzyl-di(2-chloroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride, coconut trimethyl ammonium bromide, coconut methyl dihydroxyethyl ammonium chloride, coconut methyl dihydroxyethyl ammonium bromide, decyl triethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride bromide, C_12-15dimethyl hydroxyethyl ammonium chloride, C_12-15dimethyl hydroxyethyl ammonium chloride bromide, coconut dimethyl hydroxyethyl ammonium chloride, coconut dimethyl hydroxyethyl ammonium bromide, myristyl trimethyl ammonium methyl sulphate, lauryl dimethyl benzyl ammonium chloride, lauryl dimethyl benzyl ammonium bromide, lauryl dimethyl(ethenoxy)4 ammonium chloride, lauryl dimethyl(ethenoxy)4 ammonium bromide, N-alkyl (C_12-18)dimethylbenzyl ammonium chloride, N-alkyl (C_14-18)dimethyl-benzyl ammonium chloride, N-tetradecylidmethylbenzyl ammonium chloride monohydrate, dimethyl didecyl ammonium chloride, N-alkyl and (C_12-14) dimethyl 1-napthylmethyl ammonium chloride, trimethylammonium halide, alkyl-trimethylammonium salts, dialkyl-dimethylammonium salts, lauryl trimethyl ammonium chloride, ethoxylated alkyamidoalkyldialkylammonium salt, an ethoxylated trialkyl ammonium salt, dialkylbenzene dialkylammonium chloride, N-didecyldimethyl ammonium chloride, N-tetradecyldimethylbenzyl ammonium, chloride monohydrate, N-alkyl(C_12-14) dimethyl 1-naphthylmethyl ammonium chloride, dodecyldimethylbenzyl ammonium chloride, dialkyl benzenealkyl ammonium chloride, lauryl trimethyl ammonium chloride, alkylbenzyl methyl ammonium chloride, alkyl benzyl dimethyl ammonium bromide, C₁₂ trimethyl ammonium bromides, C₁₅ trimethyl ammonium bromides, C₁₇ trimethyl ammonium bromides, dodecylbenzyl triethyl ammonium chloride, poly-diallyldimethylammonium chloride (DADMAC), dimethyl ammonium chlorides, alkyldimethylammonium halogenides, tricetyl methyl ammonium chloride, decyltrimethylammonium bromide, dodecyltriethylammonium bromide, tetradecyltrimethylammonium bromide, methyl trioctylammonium chloride, POLYQUAT 10™

, tetrabutylammonium bromide, benzyl trimethylammonium bromide, choline esters, benzalkonium chloride, stearalkonium chloride compounds, cetyl pyridinium bromide, cetyl pyridinium chloride, halide salts of quaternized polyoxyethylalkylamines, MIRAPOL™

, ALKAQUAT™

, alkyl pyridinium salts;

amines, amine salts, amine oxides, imide azolinium salts, protonated quaternary acrylamides, methylated quaternary polymers, and cationic guar.

14. The composition of claim 13, wherein the at least one surface stabilizer is povidone.

15. The composition of claim 13, wherein the at least one surface stabilizer is sodium deoxycholate.

16. The composition of claim 1, wherein the at least one surface stabilizer is selected from the group consisting of poloxamer 188, poloxamer 338, poloxamer 407, polysorbate 80, and lecithin.

17. The composition of claim 1 further comprising at least one excipient.

18. The composition of claim 1, wherein the at least one surface stabilizer is a protein.

19. The composition of claim 18, wherein the surface stabilizer is an albumin.

20. The composition of claim 19, wherein the albumin is human serum albumin.

21. The composition of claim 17 wherein the at least one excipient is a sugar selected from the group consisting of sucrose, mannitol, dextrose, lactose, sorbitol, maltose, and trehalose.

22. The composition of claim 17, wherein the at least one excipient is selected from the group consisting of a bulking agent, a crystal growth inhibitor, a free radial scavenger agent, and a redispersion agent.

23. The composition of claim 17, wherein the at least one excipient is present in the amount selected from the group consisting of from about 5 to about 95, about 10 to about 95, about 20 to about 95, about 50 to about 90, about 60 to about 90, about 70 to about 90, or about 70 to about 80, measured by % w/w of the dry composition.

24. The composition of claim 1, wherein the gamma radiation provides a total dose of radiation selected from the group consisting of from about 5 to about 50 kGray, about 15 kGray to about 40 kGray, about 15 to about 30 kGray, and about 20 to about 30 kGray.

25. The composition of claim 1, wherein the gamma radiation provides a total dose of about 25 kGray.

28. The composition of claim 1, wherein the active agent is selected from the group consisting of:

(a) docetaxel analogues comprising cyclohexyl groups instead of phenyl groups at the C-3′

benzoate position, the C-2 benzoate positions, or a combination thereof;

(b) docetaxel analogues lacking phenyl or an aromatic group at C-3′

or C-2 position;

(c) 2-amido docetaxel analogues;

(d) docetaxel analogues lacking the oxetane D-ring but possessing the 4alpha-acetoxy group;

(e) 5(20)deoxydocetaxel;

(f) 10-deoxy-10-C-morpholinoethyl docetaxel analogues;

(g) analogues having a t-butyl carbamate as the isoserine N-acyl substituent, but differing from docetaxel at C-10 (acetyl group versus hydroxyl) and at the C-13 isoserine linkage (enol ester versus ester);

(h) docetaxel analogues having a peptide side chain at C3;

(i) XRP9881 (10-deacetyl baccatin III docetaxel analogue);

(j) XRP6528 (10-deacetyl baccatin III docetaxel analogue);

(k) Ortataxel (14-beta-hydroxy-deacetyl baccatin III docetaxel analogue);

(l) MAC-321 (10-deacetyl-7-propanoyl baccatin docetaxel analogue);

(m) DJ-927 (7-deoxy-9-beta-dihydro-9,10, 0-acetal taxane docetaxal analogue);

(n) docetaxel analogues having C2-C3′

N-linkages bearing an aromatic ring at position C2, and tethered between N3′ and

the C2-aromatic ring at the ortho position;

(o) docetaxel analogues having C2-C3′

N-linkages bearing an aromatic ring at position C2, and tethered between N3′ and

the C2-aromatic ring at the meta position;

(p) docetaxel analogues bearing 22-membered (or more) rings connecting the C-2OH and C-3′

NH moieties;

(q) 7beta-O-glycosylated docetaxel analogues;

(r) 10-alkylated docetaxel analogues;

(s) 2′

,2′

-difluoro docetaxel analogues;

(t) 3′

-(2-furyl) docetaxel analogues;

(u) 3′

-(2-pyrrolyl) docetaxel analogues; and

(v) fluorescent and biotinylated docetaxel analogues.

29. The composition of claim 28, wherein the docetaxel analogue is selected from the group consisting of:

(a) 3′

-dephenyl-3′

cyclohexyldocetaxel;

(b) 2-(hexahydro)docetaxel;

(c) 3′

-dephenyl-3′

cyclohexyl-2-(hexahydro)docetaxel;

(d) 3′

-dephenyl-3′

-cyclohexyldocetaxel;

(e) 2-(hexahydro)docetaxel;

(f) m-methoxy docetaxel analogues;

(g) m-chlorobenzoylamido docetaxel analogues;

(h) 5(20)-thia docetaxel analogues;

(i) docetaxel analogues in which the 7-hydroxyl group is modified to the hydrophobic group methoxy;

(j) docetaxel analogues in which the 7-hydroxyl group is modified to the hydrophobic group deoxy;

(k) docetaxel analogues in which the 7-hydroxyl group is modified to the hydrophobic group 6,7-olefin;

(l) docetaxel analogues in which the 7-hydroxyl group is modified to the hydrophobic group alpha-F;

(m) docetaxel analogues in which the 7-hydroxyl group is modified to the hydrophobic group 7-beta-8-beta-methano;

(n) docetaxel analogues in which the 7-hydroxyl group is modified to the hydrophobic group fluoromethoxy;

(o) 10-alkylated docetaxel analogue having a methoxycarbonyl group at the end of the alkyl moiety;

(p) docetaxel analogues that possess a N-(7-nitrobenz-2-oxa-1,3-diazo-4-yl)amido-6-caproyl chain in position 7 or 3′

;

(q) docetaxel analogues that possess a N-(7-nitrobenz-2-oxa-1,3-diazo-4-yl)amido-3-propanoyl group at 3′

; and

(r) docetaxel analogues that possess a 5′

-biotinyl amido-6-caproyl chain in position 7, 10 or 3′

.

26. A dry composition comprising about 18.87% docetaxel, about 4.72% povidone, about 0.94% sodium deoxycholate, about 56.60% sucrose, and about 18.87% mannitol.

27. A dry composition comprising about 18.87% docetaxel, about 4.72% povidone, about 0.94% sodium deoxycholate, about 37.74% sucrose, and about 37.74% mannitol.

30. A method for making a sterilized nanoparticulate composition comprising the steps of:

lyophilizing an aqueous dispersion comprising at least one active agent selected from the group consisting of docetaxel, salts of docetaxel, derivatives of docetaxel, conjugates of docetaxel and analogues of docetaxel, wherein the particles have an effective average particle size of less than about 2000 nm, and at least one surface stabilizer adsorbed on a surface of the particles, to form a lyo; and

sterilizing the lyo to produce a sterilized composition.

31. The method of claim 30, further comprising before the lyophilizing step, the step of mixing the at least one active agent selected from the group consisting of docetaxel, salts of docetaxel, derivatives of docetaxel, conjugates of docetaxel and analogues of docetaxel, and the at least one surface stabilizer in an aqueous medium for a period of time and under conditions sufficient to provide the aqueous dispersion.

32. The method of claim 31, wherein the mixing step is selected from the group consisting of milling, attrition, homogenizing, precipitating, supercritical fluids processing, freezing, nano-electrospraying techniques, or any combination thereof.

33. The method of claim 30, wherein the sterilizing step comprises exposing the lyo to a gamma radiation dose selected from the group consisting of from about 5 to about 50 kGray, about 15 kGray to about 40 kGray, about 15 to about 30 kGray, and about 20 to about 30 kGray.

34. The method of claim 30, wherein the sterilizing step comprises exposing the lyo to about 25 kGray of gamma radiation.

35. The method of claim 30, wherein the aqueous dispersion further comprises at least one excipient selected from the group consisting of a bulking agent, a crystal growth inhibitor, a free radical scavenger agent, and a redispersion agent.

36. The method of claim 30, wherein the aqueous dispersion before the lyophilizing step has an effective average particle size selected from the group consisting of less than about 2000 nm, less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1 micron, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, and less than about 50 nm.

37. The method of claim 30 further comprising, after the sterilizing step, the step of redispersing the lyo in an aqueous medium forming a post-sterilized dispersion having an effective average particle size selected from the group consisting of less than about 2 microns, less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1 micron, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, and less than about 50 nm.

39. A terminally sterilized lyophilization composition made from the steps comprising:

milling at least one active agent selected from the group consisting of docetaxel, salts of docetaxel, derivatives of docetaxel, conjugates of docetaxel and analogues of docetaxel, an excipient selected from the group consisting of a bulking agent, a crystal growth inhibitor, a free radical scavenger agent, a redispersion agent, and at least one surface stabilizer, with milling media in an aqueous medium for a period of time and under conditions sufficient to provide a dispersion of particles of the at least one active agent having an effective average particle size of less than about 2000 nm, and the at least one surface stabilizer adsorbed on the surface of the particles;

removing the milling media from the dispersion;

lyophilizing the dispersion to form a lyo; and

sterilizing the lyo to produce a sterilized composition.

40. The composition of claim 39, wherein the sterilizing step comprises exposing the lyo to a dose of gamma radiation effective to produce sterilization.

41. A method of treating a subject in need of docetaxel or a salt, derivative, conjugate or analogue thereof comprising administering to the subject an effective amount of a composition comprising:

(a) particles comprising docetaxel, a salt, derivative, conjugate or analogue thereof, wherein the particles have an effective average particle size of less than about 2000 nm; and

(b) at least one surface stabilizer adsorbed on a surface of the particles,

wherein the composition is sterilized by exposure to gamma radiation.

42. The method of claim 41, wherein the composition is administered by injection.

43. A sterile liquid dosage form of docetaxel for intravenous administration comprising:

(a) about 5% by weight particles of at least one active agent selected from the group consisting of docetaxel, salts of docetaxel, derivatives of docetaxel, conjugates of docetaxel and analogues of docetaxel, the particles having an effective average particle size of less than about 2000 nm;

(b) two surface stabilizers, one or both of the surface stabilizers is adsorbed on a surface of particles;

(c) sucrose; and

(d) mannitol,

wherein the composition is sterilized by exposure to gamma radiation, and wherein the composition is administered to a patient at a dosage amount selected from the group consisting of about 100, 200, 300, 400, 500, 600, 700, 800, 900 and 1000 mg/m².